Innovate 32 Aligns with Crestview Dental and Cedar Street Family Dentistry to Strengthen Growth in East Tennessee
Innovate 32 Partners with Crestview Dental and Cedar Street Family Dentistry, Continuing Momentum in East Tennessee Innovate 32 a growth-oriented dental services organization, today announced new partnerships with Crestview Dental…
Lucidis® Elevates Premium Cataract Surgery with Exceptional Full-Range Vision Performance
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening…
Syntis Bio Initiates Phase 1/1b Clinical Study of SYNT-101 in Obesity with First Patient Dosed
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics…
Esperion Therapeutics Expands Cardiovascular Franchise Through Acquisition of Corstasis Therapeutics and Enbumyst™
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical…
Amylyx Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Amylyx Pharmaceuticals, Inc. today reported financial and business results for the fourth quarter and full year ended December 31,…
Progeria Research Foundation and Forge Biologics Partner to Strengthen Gene Therapy Development for Children
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing…
Delcath Systems Reports CHOPIN Clinical Trial Results Published in The Lancet Oncology
Delcath Systems Reports Publication of CHOPIN Clinical Trial Findings in The Lancet Oncology Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic liver cancers,…
Kivu Bioscience Names Brunilda Shtylla as Chief Business Officer
Kivu Bioscience Names Brunilda Shtylla as Chief Business Officer to Lead Strategic Growth and Partnership Initiatives Kivu Bioscience, a clinical-stage biotechnology company dedicated to advancing next-generation antibody-drug conjugates (ADCs) for…
Intellia Therapeutics Secures FDA Clearance to Resume MAGNITUDE Phase 3 Trial in ATTR-CM
Intellia Therapeutics Reports FDA Clearance to Resume MAGNITUDE Phase 3 Study in ATTR-CM Following Removal of Clinical Hold Intellia Therapeutics has cleared a significant regulatory hurdle in its effort to…
Royalty Pharma Names Kenneth Sun as SVP and Head of Asia to Strengthen Global Expansion Strategy
Royalty Pharma Names Kenneth Sun as Senior Vice President and Head of Asia, Strengthening Its Global Expansion Strategy and Regional Presence Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment…
Zoetis Expands Precision Animal Health Portfolio with Acquisition of Genomics Unit from Neogen
Zoetis moves to acquire the animal genomics unit of Neogen, strengthening its precision animal health capabilities. Zoetis Inc. the world’s leading animal health company, today announced it has entered into…
Roche’s Fenebrutinib Confirms Potential as First BTK Inhibitor for MS in Third Positive Phase III Trial (FENhance 1)
Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III…